The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer

References

• Sicklick JK, Kato S, Okamura R, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019;25(5):744–750.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Towse A. A strategy to support efficient development and use of innovations in personalized medicine and precision medicine. J Manag Care Spec Pharm. 2019;25(10):1082–1087.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer [Internet]. [cited 2020 October 20]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Food and Drug Administration. Herceptin (trastuzumab) Label [Internet]. 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.
   Google Scholar
• Food and Drug Administration. FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer [Internet]. FDA; 2019 [ cited 2020 Aug 20]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pertuzumab-adjuvant-treatment-her2-positive-breast-cancer.
   Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second Panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Drevon D, Fursa SR, Malcolm AL, et al. Validity of webplotdigitizer in extracting graphed data. Behav Modif. 2017;41(2):323–339.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer. J Clin Oncol. 2016;34(9):902–909.
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Goh JW, Pan F, et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care. 2012;28(1):12–21.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer Price Index [Internet]. [ cited 2019 Aug 4]. Available from: https://www.bls.gov/cpi/.
   Google Scholar
• Centers for Medicare and Medicaid Services. 2019 ASP Drug Pricing Files [Internet]. [cited 2019 Nov 30]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles.
   Google Scholar
• Centers for Medicare and Medicaid Services. Physician Fee Schedule Look-Up Tool [Internet]. [ cited 2020 Jan 12]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSlookup/index.
   Google Scholar
• Hansen RN, Ramsey SD, Lalla D, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. SpringerPlus. 2014;3(1):259.
   PubMedGoogle Scholar
• Blumen H, Fitch K, Polkus V. Comparison of Treatment Costs for breast cancer, by tumor stage and type of service. Am Health Drug Benefits. 2016;9(1):23–32.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end of life conversations. Arch Intern Med. 2009;169(5):480–488.
   PubMedGoogle Scholar
• Garrison LP, Babigumira J, Tournier C, et al., Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of her2-positive breast cancer in the United States. Value Health J Int Soc PharmacoEcon Outcomes Res. 22:(4): 408–415. 2019.
   Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. 2020–2023 Value Assessment Framework [Internet]. 2020. [cited 2020 October 20]. Available from: https://icer-review.org/wp-content/uploads/2019/05/ICER_2020_2023_VAF_013120-1.pdf.
   Google Scholar
• Davis S. Assessing Technologies That Are Not Cost-Effective at a Zero Price [Internet]. National Institute for Health and Care Excellence (NICE): NICE Decision Support Unit Methods Development; 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310371/pdf/Bookshelf_NBK310371.pdf.
   Google Scholar
• Babigumira JB, Santos E, Antao VP, et al. Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. J Clin Oncol. 2014;32(15_suppl):642.
   Web of Science ®Google Scholar
• Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health J Int Soc PharmacoEcon Outcomes Res. 2009;12(8):1118–1123.
   Web of Science ®Google Scholar
• Pearson SD, Dreitlein WB, Henshall C, et al., Indication-specific pricing of pharmaceuticals in the US healthcare system. J Comp Eff Res. 6(5): 397–404. 2017.
   PubMed Web of Science ®Google Scholar
• Woodward N, De Boer RH, Redfern A, et al. Results from the first multicenter, open-label, phase iiib study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with her2-positive metastatic Breast cancer (SAPPHIRE). Clin Breast Cancer. 2019;19(3):216–224.
   PubMed Web of Science ®Google Scholar
• Tan AR, Im S-A, Mattar A, et al. Abstract PD4-07: subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. Cancer Res. 2020; 80: PD4-07-PD4–07.
   Google Scholar
• Barbier L, Declerck P, Simoens S, et al. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019;121(3):199–210.
   PubMed Web of Science ®Google Scholar
• Dankó D, Blay J-Y, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy Amst Neth. 2019;123(12):1230–1236.
   PubMed Web of Science ®Google Scholar
• Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–165.
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(1):139.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, et al. Defining elements of value in health care—a health economics approach: an iSpor special task force report [3]. Value Health. 2018;21(2):131–139.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793–799.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;72:102346.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Zamora B, Li M, et al. Augmenting cost-effectiveness analysis for uncertainty: the implications for value assessment-rationale and empirical support. J Manag Care Spec Pharm. 2020;26(4):400–406.
   PubMed Web of Science ®Google Scholar